Contents

Preface ix

1 Introduction to Theory in Medicine 1
  1.1 Introduction ................................................. 1
  1.2 Disease ......................................................... 3
  1.3 A brief survey of trends in health and disease ............ 4
  1.4 The scientific basis of medicine .............................. 10
  1.5 Aspects of the medical art ..................................... 11
  1.6 Key scientific concepts in mathematical medicine ........ 12
    1.6.1 Genetics .................................................. 13
    1.6.2 Evolution ................................................ 17
  1.7 Pathology—where science and art meet ...................... 21
References ...................................................... 22

2 Introduction to Cancer Modeling 25
  2.1 Introduction to cancer dynamics .............................. 25
  2.2 Historical roots ................................................. 26
    2.2.1 The von Bertalanffy growth model ...................... 26
    2.2.2 Gompertzian growth ...................................... 28
  2.3 Applications of Gompertz and von Bertalanffy models ..... 33
  2.4 A more general approach ...................................... 39
  2.5 Mechanistic insights from simple tumor models .......... 42
  2.6 Sequencing of chemotherapeutic and surgical treatments ... 44
  2.7 Stability of steady states for ODEs ......................... 48
  2.8 Exercises ...................................................... 52
  2.9 Projects and open questions .................................. 58
    2.9.1 Mathematical open questions ......................... 60
    2.9.2 Tumor growth with a time delay ..................... 61
    2.9.3 Tumor growth with cell diffusion .................... 61
References ...................................................... 61

3 Spatially Structured Tumor Growth 65
  3.1 Introduction .................................................... 65
  3.2 The simplest spatially structured tumor model ............ 66
    3.2.1 Model formulation ...................................... 66
    3.2.2 Equilibrium nutrient profile with no necrosis ...... 69
    3.2.3 Size of the necrotic core .............................. 71
3.3 Spheroid dynamics and equilibrium size .......................... 72
3.4 Greenspan’s seminal model ........................................... 77
  3.4.1 The Greenspan model ........................................... 78
  3.4.2 Threshold for quiescence ..................................... 80
  3.4.3 Growth dynamics of the Greenspan model ................. 81
3.5 Testing Greenspan’s model .......................................... 83
3.6 Sherratt-Chaplain model for avascular tumor growth ........... 84
  3.6.1 MATLAB® file for Figure 3.6 ............................... 86
  3.6.2 Minimum wave speed ......................................... 88
3.7 A model of in vitro glioblastoma growth ......................... 89
  3.7.1 Model formulation ............................................. 89
  3.7.2 Traveling wave system properties .......................... 91
  3.7.3 Existence of traveling wave solutions .................... 92
3.8 Derivation of one-dimensional conservation equation ........... 96
3.9 Exercises ............................................................ 98
3.10 Projects ............................................................ 102
  3.10.1 Nutrient limitation induced quiescence .................... 103
  3.10.2 Inhibitor generated by living cells ........................ 103
  3.10.3 Glioblastoma growth in a Petri dish or in vivo ........... 103
  3.10.4 A simple model of tumor-host interface .................. 103
References ......................................................................... 105

4 Physiologically Structured Tumor Growth .......................... 107
  4.1 Introduction ........................................................... 107
  4.2 Construction of the cell-size structured model ................. 108
  4.3 No quiescence, some intuition ................................... 112
  4.4 Basic behavior of the model ..................................... 114
  4.5 Exercises ............................................................ 119
References ......................................................................... 120

5 Prostate Cancer: PSA, AR, and ADT Dynamics ...................... 123
  5.1 Introduction ........................................................... 123
  5.2 Models of PSA kinetics ............................................. 124
    5.2.1 Vollmer et al. model ......................................... 125
    5.2.2 Prostate cancer volume ...................................... 125
  5.3 Dynamical models .................................................... 127
    5.3.1 Swanson et al. model ......................................... 127
    5.3.2 Vollmer and Humphrey model ............................. 130
    5.3.3 PSA kinetic parameters: Conclusions from dynamical models ............................................. 133
  5.4 Androgens and the evolution of prostate cancer ............... 136
    5.4.1 Evolutionary role .............................................. 137
    5.4.2 Intracellular AR kinetics model ............................ 138
    5.4.3 Basic dynamics of the AR kinetics model ............... 140
  5.5 Prostate growth mediated by androgens ........................ 141
5.6 Evolution and selection for elevated AR expression 146
   5.6.1 Model 146
   5.6.2 Results 147
5.7 Jackson ADT model 148
5.8 The Ideta et al. ADT model 152
5.9 Predictions and limitations of current ADT models 155
5.10 An immunotherapy model for advanced prostate cancer 156
5.11 Other prostate models 161
5.12 Exercises 163
5.13 Projects 167
   5.13.1 The epithelial-vascular interface and serum PSA 167
   5.13.2 A clinical algorithm based on a dynamical model 168
   5.13.3 An extension of Vollmer and Humphrey’s model 168
   5.13.4 Androgens positively regulating AI cell proliferation 169
   5.13.5 Combining androgen ablation with other therapies 169
References 170

6 Resource Competition and Cell Quota in Cancer Models 175
6.1 Introduction 175
6.2 A cell-quota based population growth model 176
6.3 From Droop cell-quota model to logistic equation 180
6.4 Cell-quota models for prostate cancer hormone treatment 183
   6.4.1 Preliminary model 183
   6.4.2 Final model 184
   6.4.3 Simulation 185
   6.4.4 Predictions 187
6.5 Other cell-quota models for prostate cancer hormone treatment 188
   6.5.1 Basic model 188
   6.5.2 Long-term competition in the basic model 189
   6.5.3 Intermittent androgen deprivation 190
   6.5.4 Cell quota with chemical kinetics 192
6.6 Stoichiometry and competition in cancer 193
   6.6.1 KNE model 194
   6.6.2 Predictions 196
6.7 Mathematical analysis of a simplified KNE model 198
6.8 Exercises 202
6.9 Projects 207
   6.9.1 Beyond the KNE model 207
   6.9.2 Iodine and thyroid cancer 208
   6.9.3 Iron and microbes 208
References 210
7 Natural History of Clinical Cancer

7.1 Introduction .................................................. 213
7.2 Conceptual models for the natural history of breast cancer:
   Halsted vs. Fisher ............................................. 214
   7.2.1 Surgery and the Halsted model ......................... 215
   7.2.2 Systemic chemotherapy and the Fisher model .......... 217
   7.2.3 Integration of Halsted and Fisher concepts: Surgery
       with adjuvant chemotherapy ............................... 218
7.3 A simple model for breast cancer growth kinetics ............ 219
   7.3.1 Speer model: Irregular Gompertzian growth .......... 220
   7.3.2 Calibration and predictions of the Speer model ...... 221
   7.3.3 Limitations of the Speer approach ................... 222
7.4 Metastatic spread and distant recurrence ..................... 223
   7.4.1 The Yorke et al. model ................................. 223
   7.4.2 Parametrization and predictions of the Yorke model .. 226
   7.4.3 Limitations of the Yorke approach ................... 227
   7.4.4 Iwata model .............................................. 227
   7.4.5 Thames model ........................................... 231
   7.4.6 Other models ............................................. 231
7.5 Tumor dormancy hypothesis ................................... 231
7.6 The hormonal environment and cancer progression ............ 235
7.7 The natural history of breast cancer and screening protocols 236
   7.7.1 Pre-clinical breast cancer and DCIS ................. 238
   7.7.2 CISNET program ......................................... 238
   7.7.3 Continuous growth models ............................. 240
   7.7.4 Conclusions and optimal screening strategies ........ 245
7.8 Cancer progression and incidence curves ...................... 246
   7.8.1 Basic multi-hit model .................................. 246
   7.8.2 Two-hit models ......................................... 248
   7.8.3 The case of colorectal cancer ......................... 251
   7.8.4 Multiple clonal expansions ............................ 254
   7.8.5 Smoking and lung cancer incidence ................... 254
   7.8.6 Summary ................................................. 255
7.9 Exercises ..................................................... 256
References ....................................................... 258

8 Evolutionary Ecology of Cancer

8.1 Introduction .................................................. 265
8.2 Necrosis: What causes the tumor ecosystem to collapse? .... 266
   8.2.1 Necrosis in multicell spheroids ....................... 268
   8.2.2 Necrosis in tumor cords ............................... 270
   8.2.3 Diffusion limitation in ductal carcinoma in situ ...... 272
   8.2.4 Necrosis caused by mechanical disruption of cells ...... 273
   8.2.5 Necrosis from local acidosis .......................... 276
   8.2.6 Necrosis due to local ischemia ....................... 277
8.3 What causes cell diversity within malignant neoplasia? 280
8.3.1 Causes of Type I diversity 280
8.3.2 Causes of Type II diversity 286
8.4 Synthesis: Competition, natural selection and necrosis 295
8.5 Necrosis and the evolutionary dynamics of metastatic disease 297
8.5.1 Pre-metastatic selection hypothesis 298
8.5.2 Reproductive fitness and export probability 300
8.5.3 Tumor self-seeding 301
8.6 Conclusion 302
8.7 Exercises 303
References 304

9 Models of Chemotherapy 313
9.1 Dose-response curves in chemotherapy 314
9.1.1 Simple models 314
9.1.2 Concentration, time, and cytotoxicity plateaus 317
9.1.3 Shoulder region 317
9.1.4 Pharmacodynamics for antimicrobials 318
9.2 Models for in vitro drug uptake and cytotoxicity 318
9.2.1 Models for cisplatin uptake and intracellular pharmacokinetics 319
9.2.2 Paclitaxel uptake and intracellular pharmacokinetics 320
9.3 Pharmacokinetics 323
9.4 The Norton-Simon hypothesis and the Gompertz model 327
9.4.1 Gompertziian model for human breast cancer growth 328
9.4.2 The Norton-Simon hypothesis and dose-density 328
9.4.3 Formal Norton-Simon model 329
9.4.4 Intensification and maintenance regimes 331
9.4.5 Clinical implications and results 331
9.4.6 Depletion of the growth fraction 332
9.5 Modeling the development of drug resistance 333
9.5.1 Luria-Delbrück fluctuation analysis 333
9.5.2 The Goldie-Coldman model 338
9.5.3 Extensions of Goldie-Coldman and alternating therapy 340
9.5.4 The Monro-Gaffney model and palliative therapy 347
9.5.5 The role of host physiology 350
9.6 Heterogeneous populations: The cell cycle 351
9.6.1 The Smith-Martin conceptual model 351
9.6.2 A delay differential model of the cell cycle 353
9.6.3 Age-structured models for the cell cycle 355
9.6.4 More general sensitivity and resistance 358
9.7 Drug transport and the spatial tumor environment 359
9.7.1 Solute transport across tumor capillaries 359
9.7.2 Fluid flow in tumors 361
9.7.3 Tumor spheroid 362
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.7.4  Tumor cord framework</td>
<td>362</td>
</tr>
<tr>
<td>9.8   Exercises</td>
<td>363</td>
</tr>
<tr>
<td>References</td>
<td>364</td>
</tr>
</tbody>
</table>

10 Major Anticancer Chemotherapies 371

| 10.1 Introduction                            | 371  |
| 10.2 Alkylating and alkalating-like agents   | 372  |
| 10.2.1 Nitrogen mustards                     | 373  |
| 10.2.2 Platinum-based drugs                  | 375  |
| 10.2.3 Nitrosoureas                           | 376  |
| 10.2.4 Methylating agents                    | 377  |
| 10.3 Antitumor antibiotics                   | 377  |
| 10.3.1 Anthracyclines                        | 378  |
| 10.3.2 Mitomycin-C                           | 378  |
| 10.3.3 Bleomycins                            | 378  |
| 10.4 Antimetabolites                         | 380  |
| 10.5 Mitotic inhibitors                      | 380  |
| 10.5.1 Taxanes                               | 380  |
| 10.5.2 Vinca alkaloids                       | 382  |
| 10.6 Non-cytotoxic and targeted therapies     | 383  |
| References                                   | 383  |

11 Radiation Therapy 389

| 11.1 Introduction                            | 389  |
| 11.2 Molecular mechanisms                    | 393  |
| 11.2.1 Ions and radical reactions            | 394  |
| 11.2.2 Oxygen status                         | 397  |
| 11.2.3 The four R's                          | 398  |
| 11.3 Classical target-hit theory             | 398  |
| 11.4 Lethal DNA misrepair                    | 400  |
| 11.4.1 Repair-misrepair model                | 400  |
| 11.4.2 Lethal-potentially lethal model       | 406  |
| 11.4.3 Parametrization                       | 407  |
| 11.5 Saturable and enzymatic repair          | 408  |
| 11.5.1 Haynes model                          | 409  |
| 11.5.2 Goodhead model                        | 410  |
| 11.5.3 General saturable-repair model        | 411  |
| 11.6 Kinetics of damage repair               | 411  |
| 11.7 The LQ model and dose fractionation     | 414  |
| 11.8 Applications                            | 419  |
| 11.8.1 Tumor cure probability                | 420  |
| 11.8.2 Regrowth                              | 420  |
| 11.8.3 Hypoxia                               | 423  |
| 11.8.4 Radiation with chemotherapy           | 423  |
| References                                   | 425  |
12 Chemical Kinetics 429
   12.1 Introduction and the law of mass action 429
       12.1.1 Dissociation constant 432
   12.2 Enzyme kinetics 432
       12.2.1 Equilibrium approximation 433
   12.3 Quasi-steady-state approximation 434
       12.3.1 Turnover number 435
       12.3.2 Specificity constant 435
       12.3.3 Lineweaver-Burk equation 435
   12.4 Enzyme inhibition 437
       12.4.1 Competitive inhibition 437
       12.4.2 Allosteric inhibition 438
   12.5 Hemoglobin and the Hill equation 440
   12.6 Monod-Wyman-Changeux model 442
   References 444

13 Epilogue: Toward a Quantitative Theory of Oncology 447
   References 452

Index 454